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Dabigatran was proven to have similar effect on the prevention of recurrence of venous
thromboembolism (VTE) and a lower risk of bleeding compared to vitamin K antagonists
(VKA). The aim of this study is to assess the cost-effectiveness (CE) of dabigatran for the
treatment and secondary prevention in patients with VTE compared to VKAs in the Dutch
setting.
Methods
Previously published Markov model was modified and updated to assess the CE of dabiga-
tran and VKAs for the treatment and secondary prevention in patients with VTE from a soci-
etal perspective in the base-case analysis. The model was populated with efficacy and
safety data from major dabigatran trials (i.e. RE-COVER, RECOVER II, RE-MEDY and RE-
SONATE), Dutch specific costs, and utilities derived from dabigatran trials or other pub-
lished literature. Univariate, probabilistic sensitivity and a number of scenario analyses
evaluating various decision-analytic settings (e.g. the perspective of analysis, use of antico-
agulants only for treatment or only for secondary prevention, or comparison to no treat-
ment) were tested on the incremental cost-effectiveness ratio (ICER).
Results
In the base-case scenario, patients on dabigatran gained an additional 0.034 quality
adjusted life year (QALY) while saving €1,598. Results of univariate sensitivity analysis
were quite robust. The probability that dabigatran is cost-effective at a willingness-to-pay
threshold of €20,000/QALY was 98.1%. From the perspective of healthcare provider,
extended anticoagulation with dabigatran compared to VKAs was estimated at €2,158 per
PLOS ONE | DOI:10.1371/journal.pone.0163550 October 24, 2016 1 / 20
a11111
OPENACCESS
Citation: Stevanović J, de Jong LA, Kappelhoff BS,
Dvortsin EP, Voorhaar M, Postma MJ (2016)
Dabigatran for the Treatment and Secondary
Prevention of Venous Thromboembolism; A Cost-
Effectiveness Analysis for the Netherlands. PLoS
ONE 11(10): e0163550. doi:10.1371/journal.
pone.0163550
Editor: Hua Zhou, Macau University of Science and
Technology, MACAO
Received: October 7, 2015
Accepted: September 11, 2016
Published: October 24, 2016
Copyright: © 2016 Stevanović et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: This study was funded by Boehringer
Ingelheim NL. The funder provided support in the
form of salaries for authors BSK and MV, but did
not have any additional role in the study design,
data collection and analysis, decision to publish, or
preparation of the manuscript. The specific roles of
these authors are articulated in the ‘author
contributions’ section.
QALY gained. The ICER for anticoagulation versus no treatment in patients with equipoise
risk of recurrent VTE was estimated at €33,379 per QALY gained. Other scenarios showed
dabigatran was cost-saving.
Conclusion
From a societal perspective, dabigatran is likely to be a cost-effective or even cost-saving
strategy for treatment and secondary prevention of VTE compared to VKAs in the
Netherlands.
Introduction
Venous thromboembolism (VTE) can manifest as deep vein thrombosis (DVT) and/or pulmo-
nary embolism (PE) [1]. The health burden associated with VTE is mostly determinedwith the
risk of a fatal PE and risk of considerable long-termmorbidity associated with the development
of post thrombotic syndrome (PTS) or chronic thromboembolic pulmonary hypertension
(CTEPH). Moreover, recurrent DVT (rDVT) occurs in approximately 7% of patients per year
and reaches to about one quarter to one third of patients within 8 years [2,3]. The health related
quality of life (HRQoL) in VTE patients is also affected. For example, a Dutch study found dis-
tinctly lower HRQoL scores measured with SF-36 questionnaires in patients with PE compared
to the general population on the subscales: social functioning, emotional, general health, physi-
cal and vitality [4].
In the Netherlands, the DVT incidence was estimated at approximately 16,000 to 20,000
cases per year [5]. Though, the overall incidence of PE in the Netherlands is unknown, a survey
among Dutch pulmonologists/internists indicated an incidence of suspected PE at 2.6 per
1,000 patients per year [2], while in general practice, 0.2 PEs per 1,000 patients were reported
[6].
Both national and international guidelines recommend anticoagulation therapy as an effec-
tive measure to prevent thrombus propagation and recurrence in VTE patients [1,2]. For the
initial treatment phase of VTE, low-molecular-weight heparins (LMWHs) for at least 5 days
combined with subsequent administration of vitamin K antagonists (VKAs; e.g. warfarin, ace-
nocoumarol or phenprocoumon), or rivaroxaban are recommended. For the maintenance
phase, the use of VKAs or rivaroxaban is recommended for at least three months [1,7]. The
need to continue anticoagulation should be re-assessed in patients based on individual patients’
risk-benefit balance every three months as there is no strong nor clear differentiation between
treatment and prevention phases [1,7].
VKAs present a highly effective anticoagulation treatment with low acquisition costs and
conventional bleedingmanagement. However, their use is limited by a narrow therapeutic
range as defined by the international normalised ratio (INR) between 2.0 and 3.0 and several
interactions with other drugs and food. To achieve the anticoagulant effect inside the required
INR range, regular monitoring and dose-adjustment is required for treatment with VKAs. In
the Dutch healthcare system, INR-monitoring is handled by thrombotic services or patient
self-management. Though it is considered highly effective in the Netherlands, INR-monitoring
of course directly affects expenditures from both healthcare provider and societal perspectives.
In particular, next to the costs of material, labour, nurse visits, training and material for self-
management, there are various out-of-the pocket expenses (for example travel costs of
patients) and productivity loss costs associated with monitoring visits impacting the broader
societal economic burden.
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Recently, in the RE-COVER and RE-COVER II trials, dabigatran, a novel oral anticoagulant
(NOAC) was shown to have similar effect on VTE recurrence and a lower risk of for clinically
relevant non-major bleeding (CRNMB) and for any bleeding compared to VKA [8,9]. When
administered for the extended treatment in patients with VTE who had completed at least
three months of initial therapy, dabigatran was non-inferior in preventing rVTE events and
showed a better safety profile than VKA (the RE-MEDY trial) in high risk patients (increased
risk for rVTE), but a significantly better efficacy in preventing rVTE and higher risk of bleed-
ings than placebo (the RE-SONATE trial) [10].
Importantly, both health and economic consequences associated with the use of dabigatran
compared to VKAs need to be considered when choosing the optimal treatment strategy. A
formal pharmacoeconomic comparison of the two anticoagulant treatments should be con-
ducted to account for all the relevant health consequences such as likelihoodof rVTE, bleed-
ings, PTS, CTEPH, death and other adverse events, as well as all relevant cost parameters
including the costs of drugs, administration, INR-monitoring, event-related costs and various
indirect costs.
The aim of this study is to assess the cost-effectiveness (CE) of dabigatran for the treatment




A previously publishedMarkov model was modified and updated to assess the CE of dabiga-
tran and VKAs for the treatment and secondary prevention of DVT and PE in the Dutch set-
ting [11]. The health states included in the model were: index VTE, rVTE,major or clinically
relevant bleeding (MCRB), CTEPH, PTS, other adverse events (i.e. myocardial infarction (MI),
unstable angina (UA) and dyspepsia), off-treatment and death from other causes (Fig 1).
In the base-case, the use of dabigatran was compared to VKAs for up to 6 months of treat-
ment followed by up to 18 months of secondary prevention in high risk patients. The flow of
patients with an index VTE event through the Markov model is detailed elsewhere [11]. The
proportion of high risk in patients with VKA or dabigatran were balanced via randomization
in the study and kept the same in the model. Shortly, at the start of the simulation, a hypotheti-
cal cohort of 10,000 adult patients (mean age 54.7 years [8,9]) for whom at least 6 months of
anticoagulant therapy was considered appropriate entered the model following an index VTE
(i.e. index DVT or index PE) event and received initial treatment with LMWHs followed by
either dabigatran or VKAs. The duration of treatment with LMWHs was assumed to be 5 days in
the dabigatran treatment arm following the summaries of product characteristics (SCPs) for
dabigatran, and 9 days in the VKAs arm in line with the RE-COVER trials. Patients in the index
VTE state were exposed to the risk of rVTE,MCRB, CTEPH, PTS, other adverse events, treat-
ment discontinuation and death from other causes. After the initial 6 months of treatment,
patients who remained in the index health state were simulated to receive up to 18 months of
anticoagulants for secondaryprevention, reflectingpatient profiles from the RE-MEDY trial [10].
rVTE could occur in any model cycle, however, the model was restricted to a maximum of
two rVTEs [12]. Furthermore, a distinctionwas made between different forms of rVTE: fatal
VTE, non-fatal PE, proximal DVT and distal DVT. After a first rVTE, patients from both treat-
ment arms were assumed to stop the initial treatment and initiate or reinitiate a 6 months stan-
dard treatment course of LMWHs, followed by VKAs.
For patients experiencing aMCRB, a distinctionwas made between an intracranial haemor-
rhage (ICH), other major bleed (MB), and a CRNMB.We did not differentiate between high
Dabigatran; A Cost-Effectiveness Analysis for the Netherlands
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and low risk MCRB, as the clinical trial populations were balanced via randomization in terms
of baseline bleeding risks. Regarding the VTE risk, we refer to the inclusion criteria for
RECOVER,where planned treatment duration should be at least 6 months; that allows to
assume that the same patient population can continue to be treated for a longer period [8,9].
Subsequently, the calibration of incidences was not applied, as low risk groups were tested in a
separate scenario. If ICH occurred, in the model it could lead to permanent disability, death, or
recovery. MBs were modelled to lead to death or recovery. Furthermore, it was assumed that
patients can experience up to two major bleeds (ICH or MB) during the entire time they may
spend on anticoagulation; one event could be experiencedduring treatment phase with study
medication and one event during LMWHs/VKAs re-treatment [12]. CRNMB could occur at
everymodel cycle while on anticoagulation [12]. After a MB or ICH, all patients were assumed
to discontinue treatment altogether having no further risk of bleeding, but continuing to be
exposed to a risk of rVTE.Other adverse events of anticoagulant therapy captured by the model
are UA, MI and dyspepsia. Patients with a non-fatal MI or UA could suffer from chronic ische-
mic heart disease (IHD), or recover. Mortality after IHD was assumed to be part of the popula-
tion mortality in the model. In the model, all patients who experienced a first or recurrent PE
(rPE) were at risk to develop CTEPH, while those with an index or rDVT were at risk of PTS.
During treatment or secondary prevention phases, all patients could discontinue treatment
prior to reaching the maximum planned duration of treatment due to reasons other than rVTE
or ICH/MB. If discontinuation occurs, patients move to the off-treatment state where they con-
tinue to experience a risk of rVTE, but no further risk of bleeds. Finally, patients in any of the
health states were at risk to die from other causes. Patient movement between health states was
modeled using 1-month cycles until death.
The final outcome of the decisionmodel is the incremental cost-effectiveness ratio (ICER)
of dabigatran compared to VKAs. Quality-adjusted life-years (QALYs) and life-years (LYs)
Fig 1. Markov model. VTE, venous thromboembolism; DVT, deep vein thrombosis; PE, pulmonary
embolism; r, recurrent; LMWH, low molecular weight heparin; CRNMB = clinically relevant non-major bleed
event; ICH = intracranial haemorrhage; MB = major bleed; MI = myocardial infarction; CTEPH = chronic
thromboembolic pulmonary hypertension; PTS = post thrombotic syndrome; UA, unstable angina; IHD,
ischemic heart disease.
doi:10.1371/journal.pone.0163550.g001
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gained were estimated as a measure of effectiveness.All relevant costs reflect a societal perspective
in the base-case analysis and are inflated, if necessary, to price year 2013 using the Dutch con-
sumer price index [13]. Future costs and health effects were discounted by 4% and 1.5% annually
after the first year, according to the Dutch guidelines for pharmacoeconomic research [14].
Transition probabilities
In the base-case, to estimate the transition probabilities between the health states in the model
during the treatment and prevention phases, data were used from a published meta-analysis of
the RE-COVER and RE-COVER II trials [8,9] and the RE-MEDY trial [10], respectively. This
was in line with the previously publishedMarkov model [11].
In particular, the baseline probabilities of rVTE and MCRB were calculated from the
observed incidence in the VKA arm of the aforementioned trials. For the treatment phase, the
incidences of rVTE and MCRB were log transformed with respect to time, to better reflect the
occurrence pattern of these events in the trials. For the secondary prevention phase, the inci-
dences were not varied with time. To calculate the probabilities of events while on dabigatran,
the estimated treatment effect (hazard ratio (HR)) for each trial endpoint was applied to the
risk in the VKA arm (Table 1).
Furthermore, the probabilities of having a fatal VTE, non-fatal PE, proximal DVT, or distal
DVT, were based on the incidences of these events in the aforementioned trials, and they were
modelled to be conditional on having a VTE event. Similarly, the probabilities of having an
ICH, other MB, fatal MB (including ICH) or CRNMBwere conditional on having a MCRB.
The proportion of ICH leading to permanent disability was assumed to be 65.3% [15].
Beyond the duration of the anticoagulant treatment, the lifetime probability of rVTEwas
calculated from the assumed 10-year cumulative incidence of 39.9% [16], assuming a constant
hazard. The risk of bleeding after treatment discontinuation was assumed at zero for simplifi-
cation, as the risk of bleeding will be equal in both arms and will not impact incremental
QALYs. Probabilities of MI, UA and dyspepsia were estimated from the dabigatran trials [8–
10]. For the treatment followed by secondary prevention, probabilities of MI, fatal MI and UA
were calculated as the sum of probabilities in the treatment and secondary prevention trials.
Events were assumed to occur at a constant rate during the trial follow-up. For simplicity,
events were assigned to occur at the midpoint (i.e., three months). Additionally, we assumed
14% of MIs and UAs would lead to IHD [17].
The rate for CTEPH for index PE was estimated at 3.8% for two years [18]. For patients
experiencingnon-fatal rPE events, the risk of CTEPH was applied monthly up to 2 years [18].
Published evidence suggests that mild PTS has little detrimental effect on HRQoL [6], there-
fore, the model included only severe PTS. For all patients in index DVT, the 5-year rate of PTS
was estimated to be 8.1% at model start [19]. A monthly probability of PTS subsequent to non-
fatal rDVT events was applied up to 5 years [19]. Finally, the probability of death due to other
causes was obtained from Statistics Netherlands.
Utilities
Table 2 summarises the utilities used in the model. Patients were assigned baseline age- and
gender-specific utilities derived from the general Dutch population [20]. These estimates
formed the baseline from which the utility decrements associated with VTE, bleeding and
other adverse events were subtracted.
Utility decrements associated with index and rVTE,MB and CRNMBwere based on a
meta-analysis of EQ-5D data collected in the RE-COVER and RE-COVER II trials and applied
in the model similarly to the previously published study [11].
Dabigatran; A Cost-Effectiveness Analysis for the Netherlands
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Table 1. Distribution and parameter limits for the transition probabilities in the model as used in the probabilistic sensitivity analysis. CI, confi-
dence interval; r VTE, recurrent venous thromboembolism; MCRB, major or clinically relevant bleeding; VKA, vitamin K antagonists; HR, hazard ratio; D,
Dirichlet distribution applying to 2 or 3 linked probabilities with the parameter corresponding to the specific marginal Beta distribution in italics; DVT, deep
vein thrombosis; PE, pulmonary embolism; CRNMB = clinically relevant non-major bleed event; ICH = intracranial haemorrhage; MB = major bleed;
MI = myocardial infarction; UA, unstable angina; CTEPH = chronic thromboembolic pulmonary hypertension; PTS = post thrombotic syndrome.
Clinical variable Value CI (95%) Distribution Reference
Incidence of rVTE (baseline risk), treatment 2.43% - Beta(α = 62,β = 2492) [8,9]
Incidence of MCRB (baseline risk), treatment 7.68% - Beta(α = 189,β = 2273) [8,9]
Treatment effects
Treatment phase
rVTE, dabigatran vs VKA (HR) 1.09 0.77–1.54 Normal (log scale) [8,9]
MCRB, dabigatran vs VKA (HR) 0.56 0.45–0.71 Normal (log scale) [8,9]
Secondary prevention
rVTE, dabigatran vs VKA (HR) 1.44 0.78–2.64 Normal (log scale) [10]
rVTE, dabigatran vs placebo (HR) 0.08 0.02–0.25 Normal (log scale) [10]
MCRB, dabigatran vs VKA (HR) 0.55 0.41–0.72 Normal (log scale) [10]
MCRB, dabigatran vs placebo (HR) 2.69 1.43–5.07 Normal (log scale) [10]
Type of recurrent VTE events
Treatment phase
Dabigatran
Non-fatal PE 33.80% D(23,43,2) [8,9]
Proximal DVT 63.20% D(23,43,2) [8,9]
VTE-related death 2.90% D(23,43,2) [8,9]
VKA
Non-fatal PE 33.90% D(21,38,3) [8,9]
Proximal DVT 61.30% D(21,38,3) [8,9]
VTE-related death 4.80% D(21,38,3) [8,9]
Secondary prevention
Dabigatran (RE-MEDY trial)
Non-fatal PE 34.60% D(9,16,1) [10]
Proximal DVT 61.50% D(9,16,1) [10]
VTE-related death 3.80% D(9,16,1) [10]
Dabigatran (RE-SONATE trial)
Non-fatal PE 33.30% D(1,2) [10]
Proximal DVT 66.70% D(1,2) [10]
VTE-related death 0.00% Fixed [10]
VKA
Non-fatal PE 22.20% D(4,13,1) [10]
Proximal DVT 72.20% D(4,13,1) [10]
VTE-related death 5.60% D(4,13,1)
After therapy discontinuation
Non-fatal PE 23.30% D(87,243,43) [16]
Proximal DVT 65.10% D(87,243,43) [16]
VTE-related death 11.50% D(87,243,43) [16]
Type of bleeding events
Treatment phase
Dabigatran
ICH 1.80% D(2,22,85) [8,9]
Other MB 20.20% D(2,22,85) [8,9]
Fatal MB (of other) 4.20% Beta(α = 1,β = 23) [8,9]
(Continued )
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Utility decrements following the occurrence of other adverse events (i.e. MI, UA, dyspepsia,
disabled from ICH, CTEPH, and severe PTS) were derived from the published studies and
applied additively for a specific time interval in the model [6,21–25].
Costs
In the base-case analysis, all costs were collected from a societal perspective, therefore, both
direct (inside and outside healthcare) and indirect costs were included (Table 3). Direct costs
inside healthcare included the costs related to: drugs, visits to general practitioner (GP), admin-
istration, INR-monitoring and event-related resource use. Costs of dabigatran (price per
Table 1. (Continued)
Clinical variable Value CI (95%) Distribution Reference
CRNMB 78.00% D(2,22,85) [8,9]
VKA
ICH 2.10% D(4,36,149) [8,9]
Other MB 19.00% D(4,36,149) [8,9]
Fatal MB (of other) 5.00% Beta(α = 2,β = 38) [8,9]
CRNMB 78.80% D(4,36,149) [8,9]
Secondary prevention
Dabigatran (RE-MEDY)
ICH 2.50% D(2,11,67) [10]
Other MB 13.80% D(2,11,67) [10]
Fatal MB (of other) 0.00% Fixed [10]
CRNMB 83.80% D(2,11,67) [10]
Dabigatran (RE-SONATE)
ICH 0.00% Fixed [10]
Other MB 5.60% D(2,34) [10]
Fatal MB (of other) 0.00% Fixed [10]
CRNMB 94.40% D(2,34) [10]
VKA
ICH 2.80% D(4,21,120) [10]
Other MB 14.50% D(4,21,120) [10]
Fatal MB (of other) 4.00% Beta(α = 1,β = 24) [10]
CRNMB 82.80% D(4,21,120) [10]
Other probabilities
Disabled from ICH 65.30% Beta(α = 90.8,β = 48.2) [15]
Probability of IHD after MI and UA 14% Beta(α = 19,β = 116) [17]
Cumulative incidence of CTEPH at 2 years in PE patients 3.80% Beta(α = 7,β = 184) [18]
Probability of CTEPH (per cycle) 0.16% [18]
5 years cumulative incidence of severe PTS 8.10% Beta(α = 43,β = 485) [19]
Probability of severe PTS (per cycle) 0.14% [19]
rVTE after therapy discontinuation 39.90% 35.40%–44.40% Normal (SE = 0.02) [16]
Discontinuation probabilities (per cycle)
Treatment phase
Dabigatran 2.09% Fixed [8,9]
VKA 1.91% Fixed [8,9]
Secondary Prevention
Dabigatran 1.00% Fixed [10]
VKA 0.97% Fixed [10]
doi:10.1371/journal.pone.0163550.t001
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defined daily dose at 2x 150mg), VKAs and LMWHs were taken from the official Dutch price
list (Z-index) [26]. Importantly, the price of dabigatran extracted from Z-index is established
for other registered indications of dabigatran in the Netherlands (i.e. prevention of VTE in
patients who have undergone elective total hip replacement surgery or total knee replacement
surgery, and prevention of stroke and systemic embolism in non-valvular atrial fibrillation).
Acenocoumarol and phenprocoumon are the only VKAs registered in the Netherlands, there-
fore, the cost of VKAs was estimated as a weighted average of the costs of those drugs based on
their usage in the Netherlands (80%:20%, respectively) [27]. The cost of LMWHs was assumed
as a weighted average cost of enoxaparin, dalteparin, tinzaparin and nadroparin [26]. All treat-
ment alternatives were assumed to have a cost of one initial GP visit in the first month and one
follow up visit in the 4th month of a treatment.
The cost of administration of LMWHs was estimated to reflect the costs of administration
in hospital and at home. For patients receiving LMWHs in hospital, the costs of administration
were adjusted for the percentage of patients and time they spent being hospitalized for DVT
and for PE [28]. The costs of administration at home accounted for the costs of self-injection
and costs for patients requiring a nurse visit for injection (Table 3)[28,29].
The costs of INR-monitoring reflected the costs of monitoring handled by thrombotic ser-
vices and costs for patient self-management (Table 3). In the Netherlands, self-management is
Table 2. Utility parameters applied in the model. CRNMB = clinically relevant non-major bleed event; DVT = deep vein thrombosis; ICH = intracranial
haemorrhage; LMWH = low molecular-weight heparin; MB = major bleed; MI = myocardial infarction; PE = pulmonary embolism; CTEPH = chronic thrombo-
embolic pulmonary hypertension; PTS = post thrombotic syndrome.
Parameter Value Distribution Reference
Baseline utilities
Age 18–24 years (weight for males, females) 0.976, 0.925 Fixed [20]
Age 25–34 years (weight for males, females) 0.945, 0.907 Fixed [20]
Age 35–44 years (weight for males, females) 0.953, 0.917 Fixed [20]
Age 45–54 years (weight for males, females) 0.902, 0.877 Fixed [20]
Age 55–64 years (weight for males, females) 0.913, 0.866 Fixed [20]
Age 65–74 years (weight for males, females) 0.878, 0.894 Fixed [20]
Age 75 years (weight for males, females) 0.910, 0.787 Fixed [20]
Disutility of index and recurrent DVT c 0.250 Normal (SE = 0.0054)a [11]
Disutility of index and recurrent PE c 0.250 Normal (SE = 0.0152)a [11]
Disutility of ICH or other MB d 0.130 Gamma (α = 100, β = 0.001) [11]
Disutility of disabled from ICH f 0.380 Gamma (α = 16, β = 0.024)b [21]
Disutility of CRNMB d 0.040 Gamma (α = 100, β = 0.0004) [11]
Disutility of MI d 0.063 Gamma (α = 22.57, β = 0.003) [22]
Disutility of Angina d 0.085 Gamma (α = 40.40, β = 0.002) [22]
Disutility of Dyspepsia e 0.040 Gamma (α = 16, β = 0.003) b [23]
Disutility of CTEPH d 0.440 Gamma (α = 16, β = 0.028) b [24]
Disutility of severe PTS f 0.070 Gamma (α = 39.22, β = 0.002) [6]
a Change in mean from baseline to 3 months. In the probabilistic analysis, the mean baseline and 3-month value were individually sampled from normal
distributions defined by the mean and standard error (standard error was calculated from the standard deviation and N) and the difference calculated for
each simulation.
b Variance was not reported; the standard error is assumed to be 25% of the mean.
c The duration of disutility was assumed to be 6 weeks similarly to the previously published study.
d A disutility is applied in the month of the event. Specifically, the duration of the impact of UA and MI on HRQoL was assumed to be 3 months.
e The disutility applied is assumed to last for the duration of treatment.
f A disutility is applied for the remaining lifetime.
doi:10.1371/journal.pone.0163550.t002
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Table 3. Cost parameters applied in the model. VKA, vitamin K antagonists; LMWH, low molecular weight heparins; INR, international normalised ratio;
MCRB, major or clinically relevant bleeding; DVT, deep vein thrombosis; PE, pulmonary embolism; CRNMB = clinically relevant non-major bleed event;
ICH = intracranial haemorrhage; MB = major bleed; MI = myocardial infarction; UA, unstable angina; CTEPH = chronic thromboembolic pulmonary hyperten-
sion; PTS = post thrombotic syndrome GP, general practitioner.
Cost parameters Average cost (2013, €) Rangea Reference
Medication, administration and monitoring costs
VKA (daily) 0.04 0.03–0.05 [26]
Dabigatran (daily) 2.30 Fixed [26]
LMWH (daily) 10.65 7.99–13.31 [26]
LMWH at home, self-injection (one-off training) 16.77 9.59–25.93 [29]
LMWH at home, nurse injection (per day after discharge) 17.50 10.00–27.05 [29]
LMWH, administration in clinic (per day after discharge) incl. travel costs 16.54 9.45–25.57 [29]
LMWH at home, self-injection (domiciliary care) 6.74 3.85–10.43 [29]
GP visit 30.54 17.46–47.22 [14]
INR-control self-management initial monthly cost 90.46 51.71–139.88 [14,33]
INR-control cost incl. travel costs (per visit) b 12.54 7.17–19.38 [14,33]
INR-control self-management (monthly) 12.29 7.03–19.01 [14,33]
Events costs
DVT 1,187.23 679–1,836 [32]
PE 4,221.01 2,413–6,527 [32]
ER visit 167.28 96–259 [32]
Chest x-ray 156.15 89–241 [32]
Electrocardiogram 30 17–46 [32]
Acute ICH 32,754 18,722–50,646 [21]
ICH direct mild (annually) 2,367.97 1,354–3,662 [21]
ICH direct moderate (annually) 18,268 10,442–28,247 [21]
ICH direct severe (annually) 23,353 13,348–36,110 [21]
MB 4,969 2,840–7,683 [32]
CRNMB c 31 17–47 [14]
PTS (year 1) 25,073 14,331–38,769 [32]
PTS (year 2) d 61 35–94 [14]
MI acute 5,021 4,936–5,106 [34]
MI follow up (monthly) 97 55–150 [35]
UA 5,351 5,236–5,467 [36]
Dyspepsia e 0.69 0.39–1.07 [26]
CTEPH acute f 7,121 4,070–11,011 [37]
CTEPH follow up (monthly) 84 48–130 [37]
Indirect costs
Productivity loss age group 55–60 (per hour) g 31 17–47 [14]
Productivity loss age group 60–65 (per hour) g 23 13–36 [14]
ICH informal care mild (annually) 12,369 7,070–15,462 [38]
ICH informal care moderate (annually) 16,345 9,343–25,274 [38]
ICH informal care severe (annually) 20,322 11,616–31,422 [38]
a Cost estimates that were available only as single point estimates, were assumed to follow a log-normal distribution with a coefficient of variation equal to
0.25.
b Travel costs of patients included only in the base-case.
c Assumed to be equal to the cost of a GP visit.
d Assumed to be equal to the cost of two GP visit.
e Assumed the cost of Omeprazol 20mg.
f Based on the study by Mayer et al, pulmonary endarterectomy is applied to 56.8% of cases.
g One hour of productivity loss costs was estimated as a weighted average cost for employed and non-employed population in the Netherlands in the
specific age group.
doi:10.1371/journal.pone.0163550.t003
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applied by 14.9% of patients on treatment with VKAs. Therefore, the costs of initial training
for self-management and monthly follow up costs associated with the rental of equipment were
applied for this patient population (Table 3). Resource use associated with INR-monitoring at
thrombotic services (i.e. number of visits) was based on the annual medical reports from the
Dutch thrombotic services [30][31]. In particular, in the first month of a treatment, the cost of
INR-monitoring by thrombotic services reflected an average of 5.5 visits to thrombotic services.
In follow up months (2nd until 6th month), the cost of 1.4 visits per month was assumed [30]
[31]. For the application of VKAs longer than 6 months (i.e. secondary prevention phase), the
costs of INR-monitoring by thrombotic services reflected an average of 1.4 visits per month
beyond the initial 6-month period [30,31]. Moreover, direct costs outside healthcare (i.e. travel
costs) were attributed to the nurse visits for injection of LMWHs. Acute care costs associated
with clinical events (e.g. DVT, PE, ICH, other MB, CRNMB, PTS, CTEPH,MI, UA, and dys-
pepsia) were adopted from previous costing studies conducted in the Netherlands. Patients sur-
viving acute ICH, MI, PTS and CTEPH were assigned with long-termmaintenance costs.
Indirect costs outside healthcare included: productivity loss costs, caregiver time costs for
patients experiencing ICH and travel costs for the visits of patients to thrombotic services.A
2-hour productivity loss costs were assumed for all INR-monitoring visits to thrombotic ser-
vices and all GP-related visits. Additionally, productivity loss costs associated with hospitaliza-
tions due to DVT (0.63 days), PE (7 days) and MI (5.6 days) were included. The number of
productivity loss hours for each of the aforementioned hospitalizations was estimated in order
to account for regular working hours (8 hours per day) was corrected for the weekends and the
labour-time elasticity of production according to the friction costingmethod [14,32].
Sensitivity analyses
Univariate sensitivity analyses were performed to identify the key determinants of CE by vary-
ing parameters individually over the ranges derived from their 95% confidence intervals.
Where confidence intervals and standard deviations of parameters were unavailable, the stan-
dard error was assumed to be 25% of the mean. The exceptions were made when varying dis-
count rates which were varied between 0 and 5%, and the number of days on treatment with
LMWHs which were varied between 5 and 9 days. The results were defined in terms of incre-
mental cost per QALY and are presented diagrammatically in the form of a tornado diagram.
Additionally, a probabilistic sensitivity analysis (PSA) was performed to assess the robust-
ness of the findings by performing 5000 simulations to generate ICERs in which event risks
and HRs, costs and utilities were simultaneously varied randomly within their ranges. HRs of
the even rates were sampled from a normal distribution on the log scale and other probabilities
were sampled from a beta distribution. The related distribution of the type of recurrent event
were sampled from a Dirichlet distribution. Costs were sampled from a gamma distribution.
For utilities, a gamma distribution was used, except for utilities assigned to DVT and PE, for
which a normal distribution was used. Results from the PSA were plotted on a CE plane.
Scenario analyses
To investigate the impact of applying dabigatran under different decisionmaking settings
seven scenario analyses were conducted. First scenario compared the use of dabigatran and
VKAs for treatment and secondary prevention in high risk patients from the healthcare pro-
vider perspective. Second scenario compared the use of dabigatran to VKAs for up to 6 months
of treatment only. Third scenario assessed the use of anticoagulants for up to 18 months of sec-
ondary prevention only (not considering the preceding treatment duration). In the fourth sce-
nario, the use of dabigatran for up to 6 months of secondary prevention (not considering the
Dabigatran; A Cost-Effectiveness Analysis for the Netherlands
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preceding treatment duration) was compared to placebo. Here, study population simulated the
profile of the patients in the RE-SONATE trial, i.e. low risk patients (i.e. patients for whom the
need for secondary prevention is at equipoise [10]). Data from the RE-SONATE trial were the
main sources used to estimate the transition probabilities between the health states in the
model in this scenario. In the fifth scenario disutilities associated with VKA use were applied to
the model. Furthermore, as an alternative source the costs of ICH as applied by Ten Cate-Hoek
et al. was applied to the model (scenario 6), lacking however the detailing of separate cost fig-
ures for mild, moderate and severe ICH [32]. In the last scenario the transition probabilities of
ICH were reduced to half of its base-case values.
All assumptions used in the model are summarized in Table 4.
Results
In the base-case, in a hypothetical cohort of 10,000 patients with a VTE event followed over
their lifetime starting at age 54.7 years, dabigatran averted 720 MCRBs compared with VKAs
but resulted in an additional 86 rVTEs, and 65 MIs (Table 5). A comparable number of PTS,
CTEPH and UA was observed in both dabigatran and VKAs treatment arms. Dabigatran was
associated with a projected discounted quality-adjusted life expectancy of 19.187 QALYs com-
pared with 19.154 QALYs for patients receiving VKAs.
Costs allocation across different categories indicated that costs associated with handling
rVTE, bleeding and other adverse events were the major contributors to the total expenditures.
In VKAs treatment arm, these costs were higher compared to dabigatran arm (€12,409 vs
€11,074). Expenditures for event-related costs were followed by monitoring, GP visit, produc-
tivity losses and administration costs which were higher with VKAs compared to dabigatran
(€3,512 vs. €1,140), and the total drug costs that were higher with dabigatran than VKAs
(€1,550 vs. €298). Finally, accounting for all the aforementioned cost categories resulted in the
total lifetime costs varied from €12,133 per person for VKAs to €10,209 per person for
Table 4. Overview of assumptions used in the model.
• The duration of LMWH use in the dabigatran and VKA arm was assumed to be 5 and 9 days respectively,
based on the RE-COVER trials
• Only patients who remained in the index state after 6 months initial treatment were signed up for 18
months extended treatment, reflecting patient profiles from the RE-MEDY trial
• The model was restricted to a maximum of two rVTEs per patient
• After a first rVTE, patients from both treatment arms were assumed to stop the initial treatment and initiate
or reinitiate a 6 months standard treatment course of LMWHs, followed by VKAs
• No differentiation between high and low risk MCRB
• The model was restricted to a maximum of two MBs per patient during the time on anticoagulation: one
event could be experienced during treatment phase with study medication and one event during LMWHs/
VKAs re-treatment
• CRNMB could occur at every model cycle while on anticoagulation
• After a MB all patients discontinued anticoagulation treatment, having no further risk of bleeding
• Mortality after chronic ischemic heart disease (IHD) is part of the population mortality in the model
• Patients who experience PE are at risk of CTEPH
• Patients who experience DVT are at risk of PTS
• After treatment discontinuation due to any cause patients are still at risk of rVTE, but have no bleeding risk
• Patients in any of the health states are at risk to die from other causes
• Only the risk of severe PTS is included in the model
• The cost of LMWHs was assumed as a weighted average cost of enoxaparin, dalteparin, tinzaparin and
nadroparin
• All treatment alternatives were assumed to have a cost of one initial GP visit in the first month and one
follow up visit in the 4th month of a treatment
• 2-hour productivity loss costs were assumed for all INR-monitoring visits to thrombotic services and all
GP-related visits
doi:10.1371/journal.pone.0163550.t004
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dabigatran at a discount rate of 4%. In total, savings of €1,924 and an additional 0.0339 dis-
counted QALYs per patient where observedwhen applying dabigatran compared to VKAs
(Table 6).
Sensitivity analyses
The results of univariate sensitivity analyses for the top 15 parameters by the order of influence
they have to the ICERs are presented in the form of a tornado diagram (Fig 2). Specifically, the
ICER was mostly influenced by variations in the probability of VTE-related death, probability
of MCRBs-related and probability of ICH. The results of 5,000 iterations in PSA are presented
through an incremental CE plane in Fig 3. The probability that dabigatran is cost-effective at a
willingness-to-pay (WTP) threshold of €20,000/QALY was 98.1%, and 87.2% when ICERs
with negative quality of life were counted as not cost-effective. 87.2% of the simulations are
located in the second quadrant of the CE plane, in which costs are negative and QALYs are
Table 5. Recurrent VTE, bleeding complications and other adverse events and related costs within a hypothetical patient population of 10,000
subjects receiving dabigatran and VKA over a lifetime horizon. VKA, vitamin K antagonists; VTE, venous thromboembolism; DVT, deep vein thrombo-
sis; PE, pulmonary embolism; r, recurrent; LMWH, low molecular weight heparin; CRNMB = clinically relevant non-major bleed event; ICH = intracranial
haemorrhage; MB = major bleed; MI = myocardial infarction; CTEPH = chronic thromboembolic pulmonary hypertension; PTS = post thrombotic syndrome;










Index VTE 10,000 €2,142 10,000 €2,142
All recurrent VTE 13,471 13,384
Recurrent non-fatal VTE 11,959 11,871
Non-fatal DVT 8,761 €1,071 8,713 €1,065
Non-fatal PE 3,198 €1,592 3,158 €1,570
VTE-related death 1,512 €0 1,513 €0
All MCRBs 1,351 2,071
Non-fatal MCRBs 1,342 2,052
ICH 28 €1,876 47 €3,262
Other MBs 230 €118 339 €177
CRNMBs 1,084 €9 1,665 €14
Deaths from bleeding 9 €0 19 €0
MI 86 €93 21 €23
UA 23 €23 23 €23
Dyspepsia 682 €0.05 112 €0.01
PTS 1,294 €3,482 1,290 €3,471
CTEPH 243 €667 242 €662
Medication
Investigational treatment €1,315 €24
LMWHs, index event €71 €110
Re-treatment recurrent event, VKA €12 €12
Re-treatment recurrent event, LMWHs €152 €152
Monitoring and administration
INR-monitoring, GP visits, administration and productivity loss €167 €2,507
Administration of LMWHs €43 €81
Re-treatment with VKA for recurrent event:INR-monitoring, GP
visits, administration and productivity loss
€799 €794
Administration of LMWHs €131 €130
doi:10.1371/journal.pone.0163550.t005
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Table 6. Results of the base-case and scenario analyses. VKA, vitamin K antagonists; ICER, incremental cost-effectiveness ratio; QALY, quality
adjusted life year; LY, life year.
Base-case: 6 months treatment + 18 months secondary prevention (societal perspective)
Dabigatran VKA Difference
Discounted LYs 22.053 22.025 0.0282
Discounted QALYs 19.187 19.154 0.0336
Costs (€) undiscounted 13,637 15,805 -2,168
Costs (€) discounted 10,071 11,668 -1,598
ICER (€/ LYs) Cost-saving
ICER (€/ QALYs) Cost-saving
Scenario 1: 6 months treatment + 18 months secondary prevention (healthcare provider perspective)
Discounted LYs 22.053 22.025 0.0282
Discounted QALYs 19.187 19.154 0.0336
Costs (€) undiscounted 12,115 12,307 192
Costs (€) discounted 9,051 8,978 73
ICER (€/ LYs) 2,575
ICER (€/ QALYs) 2,158
Scenario 2: 6-months treatment (societal perspective)
Discounted LYs 21.924 21.907 0.0170
Discounted QALYs 19.083 19.063 0.0197
Costs (€) undiscounted 11,974 13,024 -1,050
Costs (€) discounted 8,795 9,615 -819
ICER (€/ LYs) Cost-saving
ICER (€/ QALYs) Cost-saving
Scenario 3: 18-months secondary prevention in high-risk patients (societal perspective)
Discounted LYs 22.044 22.030 0.0144
Discounted QALYs 19.248 19.230 0.0180
Costs (€) undiscounted 10,101 11,324 -1,224
Costs (€) discounted 6,535 7,370 -835
ICER (€/ LYs) Cost-saving
ICER (€/ QALYs) Cost-saving
Scenario 4: 6-months secondary prevention vs no treatment* in patients for whom the need for secondary prevention is at equipoise (societal perspective)
Discounted LYs 21.950 21.950 0.0003
Discounted QALYs 19.169 19.165 0.0035
Costs (€) undiscounted 7,945 7,847 98
Costs (€) discounted 4,923 4,807 117
ICER (€/ LYs) 429,111
ICER (€/ QALYs) 33,379
Scenario 5: treatment disutility VKA included (societal perspective)
Discounted Lys 22.053 22.025 0.0282
Discounted QALYs 19.187 19.129 0.0583
Costs (€) undiscounted 13,637 15,805 -2,168
Costs (€) discounted 10,071 11,668 -1,598
ICER (€/ LYs) Cost-saving
ICER (€/ QALYs) Cost-saving
Scenario 6: costs ICH based on Ten Cate-Hoek et al.
Discounted Lys 22.053 22.025 0.0282
Discounted QALYs 19.187 19.154 0.0336
Costs (€) undiscounted 13,166 14,998 -1,821
(Continued )
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positive. At a WTP threshold of €50,000/QALY dabigatran is cost-effective in 87.4% of the
simulations (ICERs with negative QALYs included as not cost-effective).
Scenario analyses
The results of the scenario analyses are presented in Table 6. In the scenario comparing dabiga-
tran to VKAs for the treatment, and in the one comparing them for the secondary prevention
in high-risk patients, dabigatran remained cost-saving. The scenario including the disutility
associated with VKA treatment, as well as the last two scenarios concerning the costs and tran-
sition probabilities of ICH, also remained cost-saving. Comparing dabigatran to VKAs for
treatment and secondary prevention from the healthcare provider perspective dabigatran was
cost-effectivewith an ICER of €2,158 per QALY gained. Finally, in the scenario examining the
Table 6. (Continued)
Costs (€) discounted 9,800 11,187 -1,386
ICER (€/ LYs) Cost-saving
ICER (€/ QALYs) Cost-saving
Scenario 7: Incidence ICH events reduced to half of its base-case values
Discounted Lys 22.053 22.027 0.0266
Discounted QALYs 19.193 19.166 0.0269
Costs (€) undiscounted 12,951 14,426 -1,475
Costs (€) discounted 9,672 10,867 -1,195
ICER (€/ LYs) Cost-saving
ICER (€/ QALYs) Cost-saving
*placebo risks from the clinical trial being used
doi:10.1371/journal.pone.0163550.t006
Fig 2. Tornado diagram of ICERs from sensitivity analyses for dabigatran vs. vitamin-K antagonists,
illustrating the impact of varying each of input parameters on the ICER while holding all the other model
parameters fixed. Light grey bars show the influence of using the upper limit and dark grey bars that of the
lower limit of the input parameters investigated. The solid vertical line represents the base case incremental
costs per QALY for dabigatran compared to VKA. Horizontal bars indicate the range of incremental costs per
QALY obtained by setting each variable to the values shown while holding all other values constant. ICER,
incremental cost-effectiveness ratio; QALY, quality adjusted life year; VKA, vitamin K antagonists; VTE,
venous thromboembolism; r, recurrent; ICH = intracranial haemorrhage; MBE = major bleeding event; HR,
hazard ratio.
doi:10.1371/journal.pone.0163550.g002
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prevention of recurrent VTE in patients with equipoise risk of recurrent VTE after completion
of acute treatment, anticoagulation treatment with dabigatran compared to no treatment (pla-
cebo risks from the clinical trial being used), yielded an ICER of €33,379 per QALY gained.
Discussion
Our base-case result from the decision analysis demonstrated dabigatran may be a cost–saving
alternative to VKAs for the treatment and secondary prevention of VTE from the societal per-
spective. Patients on dabigatran gained an additional 0.0336 discountedQALYs over lifetime
and savings of €1,598. The key drivers of the CE of dabigatran relative to VKA are based on its
ability to reduceMCRBs as found in the RECOVER trials. Particularly, the use of dabigatran
resulted in 720 less all MCRB events (i.e. 19 ICHs, 109 other MBs, 582 CRNMBs and 10 deaths
from bleeding) in a cohort of 10,000 patients.
Results were sensitive to the probability of VTE-related death, MCRBs-related death and
ICH, yet, they all indicated dabigatran to be cost-saving compared to VKAs. Moreover, the
PSA showed that the likelihood of dabigatran being cost-effective at WTP threshold of €20,000
per QALY was 98.1%. This also included the cost-effective ICERs in the south eastern part of
the CE plane, in which QALYs and costs are negative. Since a reduction of quality of life is not
desirable, these ICERs might not be considered cost-effective. Therefore, the probability of
being cost-effective at a WTP thresholds of €20,000/QALY and €50,000/QALY while not low-
ering the quality of life was 87.2% and 87.4%, respectively. For economic analyses determining
the cost-effectiveness of preventive drugs, for example for vaccines, a WTP threshold of
50,000/QALY can be used [39]. In this economic evaluation dabigatran showed to be already
highly cost-effective at a WTP threshold of €20,000/QALY, leading to only a marginal increase
of being cost-effectivewith a higher threshold.
The results of the scenario analyses comparing dabigatran to VKAs for the treatment and
secondary prevention in high-risk patients of VTE, were quite robust, all indicating dabigatran
may be cost-saving alternative to VKAs. Changing the duration of anticoagulation to life long
has only a marginal impact on the ICER (results not explicitly shown). Although ICH risks
Fig 3. Incremental cost-effectiveness plane.
doi:10.1371/journal.pone.0163550.g003
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showed to be sensitive in the sensitivity analysis, the two scenarios concerning the costs and
the transition probabilities of ICH showed to be still cost-saving, However, in the scenario
examining the CE of anticoagulants for the treatment and secondary prevention from the
healthcare provider perspective, dabigatran was shown to be a cost-effective alternative to
VKAs with an ICER of €2,158 per QALY gained. Interestingly, although the variability in pro-
ductivity loss costs showed an impact on the estimated ICER in the univariate sensitivity analy-
ses, excluding these costs together with other indirect costs still led to highly cost-effective
findings in the aforementioned scenario. Finally, in the scenario examining the prevention of
recurrent VTE in patients who are at equipoise for anticoagulation treatment, treatment with
dabigatran compared to placebo was estimated with an ICER of €33,379 per QALY and may
be considered cost-effective at the proposed cost-effectiveness threshold of €50,000 per QALY
gained in the Netherlands [39]. This finding reflects the higher total costs associated with
greater number of MCRBs and drug costs in dabigatran treatment arm compared to placebo
arm.We do note that anticoagulation treatment in this population is not established, current
treatment guidelines leave the decision about treatment to the choice of physicians [2], despite
projected potential lowering of rVTEs. Further confirmations of results might definitely be
needed for this patient population before widespread use in clinical practice can be expected.
To our knowledge, this is the first study that examined the use of dabigatran compared to
VKAs for the treatment and prevention of VTE in the Dutch setting. In terms of the economic
consequences of using dabigatran compared to VKAs, our findings are similar to the ones by
Braidy et al [40]. In this study a cost-minimisation analysis investigated the use of NOACs and
VKAs for the prevention of VTE and stroke in patients with atrial fibrillation from the third-
party payer perspective in an Australian setting [40]. Dabigatran was found to be dominant
over VKA (cost savings at approximately $AUS40 per patient) in terms of cost of drug admin-
istration and therapeutic monitoring. Notably, a direct comparability between the two studies
is hampered due to differences in the underlying patients’ characteristics, safety and effective-
ness data used, country-specificcost estimates and study perspective.
Our study is confronted with several potential limitations. One limitation might be that the
duration of initial treatment with LMWHs was assumed to be different in dabigatran and
VKAs treatment arms in the base-case analysis (i.e. 5 and 9 days respectively). Notably, the
duration of treatment with LMWHs was assumed to have no impact on the effectiveness of the
follow up use of dabigatran and VKAs. We varied the duration of LMWHs treatment between
5 and 9 days for both treatment alternatives in univariate sensitivity analyses. The results
remained robust to variability in the duration of LMWHs use. Furthermore, this study simu-
lated the occurrences of all MCRBs further subdivided into ICHs, other MBs, CRNMBs and
deaths from bleeding, however, the meta-analysis of the RE-COVER trials indicated that there
was only a marginally significant reduction of MBs observed in the double-dummy period in
dabigatran arm compared to VKA. Therefore, simulating the occurrences of MBs might over-
estimate the benefits in the dabigatran arm compared to VKA. Yet, acute coronary syndromes
(i.e. MIs and UAs) were also modelled in this study although their incidence was only numeri-
cally higher with dabigatran compared to VKAs. A further potential limitation in our study
concerns the assumption that patients in both treatment arms who experience a first recurrent
VTE event would switch to a 6-months standard treatment course of LMWH followed by
VKAs. This may not always be the case and patients might alternatively be switched to other
NOACs. However, there are currently no available efficacy and safety data that could charac-
terize such a switch.
A maximum of two rVTEs over the lifetime of the patients and twoMBs during the anticoa-
gulation treatment were modelled. This assumption may be considered conservative given that
a better safety profile of dabigatran treatment would be associated with a lower number of MBs
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and consequent lower costs compared to treatment with VKAs. Another limitation concerns
treatment discontinuation that was assumed for patients who experience a MB or ICH. In a
real-life setting such a decision would likely be based on individual patient characteristics.
Finally, given the lack of specific treatment recommendations for patients experiencing
CRNMBs, the discontinuation of treatment due to CRNMBwas not modelled. Notably, in
daily practice, patients may discontinue with the treatment after a certain number of conse-
quent CRNMBs. However, as dabigatran can now be reversed by idarucizumab (Praxbind), we
postulate that the manageability is not the major contributor of severity and outcome of the
bleed, but rather the underlying disease and other disorders [41]. Notably, given all limitations
listed, further investigations could be guided by a formal value-of-information (VOI) analysis.
The current version of the model does not yet foresee in this option and we felt that the current
analysis would hardly benefit from incorporating it. Firstly and most notably, strongly differing
from UK’s NICE, the Netherlands lack a formal willingness-to-pay threshold for a QALY [42],
crucially hampering any straightforward interpretation of and inferencing from the VOI. Sec-
ondly, part of the need for further data generation is already addressed via initiation of the
RECOVER registry (phase IV clinical trial), designed to evaluate dabigatran for DVT and PE
in real life [8,9]. Finally, regarding uncertainty and within the framework of a general model
validation for NICE, we previously already analyzed inserting alternative distributions in the
PSA, showing that this had only limited impact on the results of the model [43]. In conclusion,
from a societal perspective, this modelling study suggests that the use of dabigatran for treat-
ment and secondary prevention of VTE is likely to be a cost-saving alternative to VKAs in the
Netherlands. Importantly, even when the comparison between dabigatran and VKAs was
assessed from the healthcare provider perspective, dabigatran remained highly cost-effective
with an ICER of €2,158 per QALY gained as compared to a minimalWTP threshold €20,000
per QALY. Ergo, in addition to some established advantages of dabigatran (e.g. better safety
profile than VKAs; excludes the need for INR-monitoring), our study estimated the long-term
economic benefits associated with its use. Yet, it must be acknowledged that such benefits in a
“real life” setting are still to be proven. Finally, given that dabigatran is the secondNOAC regis-
tered in Europe for the treatment and secondary prevention of VTE and further are to be
expected, further investigations are needed to estimate comparative effectiveness and CE
among the individual NOACs and as a class effect.
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